Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jerusalem Pharmaceutical CoXPAE:JPH +113.94%71 Return-on-Tangible-Asset is 5.09% as of Jun. 2026, which is 40% below its 10-year median of 8.46. GuruFocus rates XPAE:JPH with a GF Score™ of 71/100 and a GF Value™ of $2.47 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Jerusalem Pharmaceutical Co ranks better than 74.08% on this metric.
The historical rank and industry rank for Jerusalem Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
XPAE:JPH'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.27 Med: 8.46 Max: 11.09
Current: 9.01
During the past 13 years, Jerusalem Pharmaceutical Co's highest Return-on-Tangible-Asset was 11.09%. The lowest was 5.27%. And the median was 8.46%.
XPAE:JPH's Return-on-Tangible-Asset is ranked better than 74.08% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.89
vs XPAE:JPH: 9.01
Jerusalem Pharmaceutical Co (XPAE:JPH) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Jerusalem Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Jerusalem Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jerusalem Pharmaceutical Co Return-on-Tangible-Asset Chart
XPAE:JPH vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jerusalem Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jerusalem Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jerusalem Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Jerusalem Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.09% mean?
Jerusalem Pharmaceutical Co (XPAE:JPH) has a Return-on-Tangible-Asset of 5.09% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jerusalem Pharmaceutical Co and its competitors. This is 40% below median its historical median of 8.46. Over the past decade, Jerusalem Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 5.27 to 11.09. According to the industry distribution chart, Jerusalem Pharmaceutical Co ranks #261 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 25.9%.
Is Jerusalem Pharmaceutical Co's Return-on-Tangible-Asset too high?
Jerusalem Pharmaceutical Co's current Return-on-Tangible-Asset of 5.09% is 40% below median its 10-year median of 8.46. Over the past 10 years, this metric has ranged from a low of 5.27 to a high of 11.09. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.89. Jerusalem Pharmaceutical Co's value of 5.09% is 76.1% above this industry median. Based on the distribution chart, Jerusalem Pharmaceutical Co ranks #261 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jerusalem Pharmaceutical Co ranks #261 out of 1007 companies for Return-on-Tangible-Asset. This puts Jerusalem Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.89. Jerusalem Pharmaceutical Co's value of 5.09% is 76.1% above this benchmark. Historically, Jerusalem Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 5.27 to 11.09 over the past decade. While the company's 10-year median is 8.46 vs. the industry median of 2.89, Jerusalem Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.89, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jerusalem Pharmaceutical Co's current Return-on-Tangible-Asset of 5.09% is 76.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jerusalem Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jerusalem Pharmaceutical Co's current Return-on-Tangible-Asset is 5.09%, which is 40% below median its own 10-year median of 8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.47, compared to a current price of $3.53 — trading 42.9% above its estimated fair value. The current Return-on-Tangible-Asset is 5.09%, which is 40% below median its 10-year median of 8.46 and 76.1% above the Drug Manufacturers industry median of 2.89. Jerusalem Pharmaceutical Co's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current Return-on-Tangible-Asset is 5.09% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued.
The current stock price of $3.53 is trading 42.9% above its estimated GF Value™ of $2.47.
GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for XPAE:JPH:
Return-on-Tangible-Asset: 5.09% (40% below median its 10-year median of 8.46)
GF Value™: $2.47 vs. price of $3.53 (42.9% above fair value)
Industry Position: 76.1% above the Drug Manufacturers median (#261 of 1007)
No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
71GF Score
Get the complete analysis for XPAE:JPH
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:JPH has been successfully added to your 
